Pipeline

Pipeline Overview

Category Product Candidate Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Market
Virology: Liver
HCV
Protease Inhibitor

Glecaprevir*Mavyert logo

 
HBV
Core Inhibitor

EDP-514

 
Virology: Respiratory
RSV
N-Protein Inhibitor

Zelicapavir (EDP-938) RSVPEDs

 

Zelicapavir (EDP-938) RSVHR

 
L-Protein Inhibitor

EDP-323

 
COVID-19
3CL Protease Inhibitor

EDP-235 SPRINT

 
Immunology
CSU
KIT Inhibitor

 
Various
Undisclosed

 
Virology: Liver
HCV Protease Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

Glecaprevir* Mavyert logo  

HBV Core Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-514   

Virology: Respiratory
RSV N-Protein Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

Zelicapavir (EDP-938) RSVPEDs 

RSV N-Protein Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

Zelicapavir (EDP-938) RSVHR 

RSV L-Protein Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-323  

COVID-19 3CL Protease Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

EDP-235 SPRINT 

Immunology
CSU KIT Inhibitor
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

   

Various Undisclosed
Discovery Preclin Phase 1 Phase 2 Phase 3 Market

   

*Fixed-dose antiviral combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET® (U.S.) and MAVIRET® (ex-U.S.).